Quantbot Technologies LP Invests $249,000 in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Quantbot Technologies LP acquired **14,401 shares** of Structure Therapeutics Inc. valued at approximately **$249,000** in the first quarter, according to their Form 13F filing.
• Structure Therapeutics has a **market capitalization of $1.09 billion**, with a current share price of **$19.00**, and its P/E ratio stands at **-18.10**.
• Several analysts have given the stock a **"Buy" rating**, with **price targets ranging from $60.00 to $89.00**, reflecting positive sentiment in the market.

Quantbot Technologies LP bought a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,401 shares of the company's stock, valued at approximately $249,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in Structure Therapeutics by 5.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock worth $112,816,000 after purchasing an additional 203,010 shares in the last quarter. Deep Track Capital LP increased its stake in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after purchasing an additional 1,579,492 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock worth $46,782,000 after purchasing an additional 575,000 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Structure Therapeutics by 29.4% during the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock worth $38,512,000 after purchasing an additional 322,601 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $13,560,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on GPCR. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. HC Wainwright decreased their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. JMP Securities decreased their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Finally, Guggenheim cut their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Stock Up 3.1%

NASDAQ GPCR traded up $0.59 on Tuesday, hitting $19.89. The stock had a trading volume of 87,055 shares, compared to its average volume of 854,811. Structure Therapeutics Inc. Sponsored ADR has a one year low of $13.22 and a one year high of $45.37. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -18.91 and a beta of -1.89. The company's 50-day moving average is $18.95 and its two-hundred day moving average is $20.78.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.